Skip to main content

Table1 Main characteristics of included studies

From: Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis

Author(year)

Case

Age

Genotype (N)

Microsatellite instability status

PD-L1 expression

Intervention methods

WT

BRAF MU

KRAS MU

Unknown

 ≥ 1%

 < 1%

Unknown

Overman (2018)

119

58(21–88)

31

29

44

15

MSI–H 119

26

65

28

Nivolumab (PD-1)

 + Ipilimumab (CTLA-4)

Overman (2017)

74

53(44–66)

29

12

26

7

MSI–H 74

21

47

6

Nivolumab (PD-1)

Le D T (2019)

124

56(21–84)

17

14

46

–

MSI–H 124

–

–

–

Pembrolizumab (PD-1)

O’Neil (2017)

23

57(40–78)

–

–

–

–

MSI–H 1

MSS 22

23

–

–

Pembrolizumab (PD-1)

Le D T (2015)

32

54(24–79)

–

19

19

–

MSI–H 11

MSS 21

–

–

–

Pembrolizumab (PD-1)

André T (2020)

307

63(24–93)

69

77

74

90

MSI–H 307

–

–

–

Pembrolizumab (PD-1)

Fukuoka (2020)

25

55(31–77)

–

–

6

–

MSI–H 3

MSS 22

9

16

–

Nivolumab (PD-1)

 + Regorafenib

Herting (2020)

30

49(28–74)

21

0

14

26

MSI–H 2

MSS 9

Unknown 19

–

–

–

Pembrolizumab (PD-1)

 + Modified FOLFOX6

Kawazoe (2020)

50

58(25–79)

4

28

19

13

MSI–H 10

MSS 40

4

–

–

Pembrolizumab (PD-1)

 + Napabucasin"

Eng C (2019) A

183

58 (51–67)

258

9

99

–

MSI–H 3

MSS 170

Unknown 10

79

84

20

Atezolizumab(PD-L1)

 + Cobimetinib

Eng C (2019) B

90

56 (51–64)

128

3

49

–

MSI–H 3

MSS 83

Unknown 4

35

42

13

Atezolizumab(PD-L1)

Hellmann (2019)

84

56(23–79)

63

40

24

41

MSI–H 2

MSS 61

Unknown 21

–

–

–

Atezolizumab(PD-L1)

 + Cobimetinib

Patel (2021)

18

56(40–70)

–

1

12

–

MSS 18

–

–

–

Nivolumab(PD-1)

 + Rifluridine/Tipitaka (FTD/TPI)

Cousin (2021)

48

62 (26–83)

–

3

30

–

MSS 48

6

–

–

Aveluma (PD-L1)

 + Regorafenib

Chen (2020)

180

65 (36–87)

–

–

–

–

MSI–H 2

MSS 166

Unknown

12

–

–

–

Durvalumab(PD-L1) + 

Tremelimumab(CTLA-4)

Martinelli (2021)

77

–

48

19

19

3

MSI–H 3

MSS 71

Unknown 4

–

–

–

Avelumab(PD-L1)

 + cetuximab

Wang (2021)

39

52(37–69)

13

2

20

4

MSS 38

MSI–L 1

–

–

–

Toripalimab(PD-1)

 + regorafenib

  1. vs Versus, WT wild type, MU mutant, MSI-H Microsatellite instability-high, MSS microsatellite-stable, MSI-L microsatellite instability-low